Hexokinase2-engineered T cells display increased anti-tumor function

Hexokinase2-engineered T cells display increased anti-tumor function

Blog Article

BackgroundT cells face significant metabolic challenges in the tumor microenvironment (TME), where cancer cells monopolize Ski de fond - Equipement - Skis - Classic critical nutrients like glucose and amino acids.This metabolic competition supports tumor growth while impairing T-cell anti-tumor responses, partly by reducing glycolytic function.Hexokinase 2 (HK2), a key enzyme in glycolysis, plays a pivotal role in maintaining T-cell functionality.

MethodsTo enhance T-cell function, primary human T cells were genetically engineered to overexpress HK2 alongside a tumor-specific receptor.These engineered T cells were tested in vitro and in vivo to evaluate their metabolic and therapeutic efficacy.ResultsHK2-engineered T cells exhibited increased glycolytic capacity, leading to enhanced cytokine secretion, activation marker expression, and metabolic activity compared to controls.

In vivo studies using Table Runner a human tumor xenograft model demonstrated the superior therapeutic efficacy of HK2-engineered T cells, including delayed tumor growth and improved survival.ConclusionHK2 overexpression improves T-cell metabolic fitness and functionality in hostile TMEs, offering a promising foundation for the development of next-generation immunotherapies targeting T-cell metabolism.